Shipra Gandhi: How a novel strategy can modulate the chemokine milieu in the TME

Shipra Gandhi, Translational Researcher at Roswell Park Comprehensive Cancer Center, shared a post by Journal for ImmunoTherapy of Cancer on X/Twitter, adding:

”We are excited to share our findings from a clinical trial in TNBC showing how a novel strategy can modulate the chemokine milieu in the TME.”

Quoting Journal for ImmunoTherapy of Cancer‘s post:

”New JITC article: Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor micro environments for selective CTL influx.”

For the article click here.
Source: Shipra Gandhi/Twitter and Journal for ImmunoTherapy of Cancer/Twitter